Publications
142
Citations
5,354
Est. group size
~15
Recurring co-author estimate
Active years
9
Publishing since 2018
Hamzah Abu-Sbeih studies the gastrointestinal and other side effects caused by cancer immunotherapy, especially checkpoint inhibitor-related colitis and diarrhea, and how to diagnose and manage these complications without undermining cancer treatment. His work combines gastroenterology (endoscopy, microbiome-based treatments like fecal transplant) with oncology, aiming to help patients continue effective cancer therapy while controlling immune-related toxicity.
Publication output was very high around 2018-2019, then declined sharply and has remained at a low, steady level (roughly 2-9 per year) since 2021.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Chemoimmunotherapy with or without locoregional therapy for biliary tract cancer: A propensity score–matched study.
Journal of Clinical Oncology · 2026
- 401 Pan-tumor multicenter study of the impact of prior immune-related adverse events (irAEs) on safety and efficacy of subsequent antibody-drug conjugate (ADC)
Regular and Young Investigator Award Abstracts · 2025
- Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients
Gastrointestinal Endoscopy · 2024
- Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis
The Oncologist · 2024
- Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis
Science Translational Medicine · 2023
- Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
Journal for ImmunoTherapy of Cancer · 2023
- Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy
Cancers · 2023
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Cancer Cell · 2022
- Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy
Journal of Gastroenterology and Hepatology · 2022
- Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Journal for ImmunoTherapy of Cancer · 2022
- 375: CONCURRENT IMMUNE CHECKPOINT INHIBITION AND SELECTIVE IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH IMMUNE-RELATED ENTEROCOLITIS
Gastroenterology · 2022
- S720 Endoscopic Severity Score of Immune-Mediated Colitis Is More Effective in Guiding Medical Treatment Than Clinical Severity Grade
The American Journal of Gastroenterology · 2022
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Journal for ImmunoTherapy of Cancer · 2021
- Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response
Journal of the National Comprehensive Cancer Network · 2021
- Outcomes of Immune Checkpoint Inhibitor–related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections
American Journal of Clinical Oncology · 2021
- Gastroenterology×25
- Journal of Clinical Oncology×20
- The American Journal of Gastroenterology×18
- Journal for ImmunoTherapy of Cancer×13
- Gastrointestinal Endoscopy×9
- Lingbin Meng
Medicine · The Ohio State University
- Lai Wei
Medicine · The Ohio State University
- Sandip H. Patel
Medicine · The Ohio State University
- John Hays
Medicine · The Ohio State University
- Na Zhuo
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile